FatanehMajlessipourMD

Pediatric Hematology & Oncology • Los Angeles, CA

Associate Professor, Pediatrics, Cedars-Sinai Medical Center; Clinical Professor Step II, Pediatrics, David Geffen School of Medicine at UCLA

Join to view full profile

Dr. Majlessipour is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Majlessipour's full profile

Already have an account?

Office
8700 Beverly Blvd
Los Angeles, CA 90048
Phone+1 310-423-4423

Fax+1 310-967-1141
Is this information wrong?

Education & Training

Children's Hospital Los AngelesFellowship, Pediatric Hematology/Oncology, 1997 - 2000
Children's Hospital of Orange CountyResidency, Pediatrics, 1994 - 1997
Isfahan University of Medical SciencesClass of 1989, MD

Certifications & Licensure

CA State Medical License 1996 - 2026
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

Top Doctors: Los Angeles, CA Castle Connolly, 2021
Top Doctors: Los Angeles Castle Connolly, 2020

Clinical Trials

Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors Start of enrollment: 2004 Mar 25
Recruiting
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET Start of enrollment: 2007 Mar 26
Active, not recruiting
Phase 3
Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
Recruiting
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
Completed
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Recruiting
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors Start of enrollment: 2004 Feb 16
Completed
Study of Blood Samples From Newborns With Down Syndrome Start of enrollment: 2009 Feb 23
Completed
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 3
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Start of enrollment: 2010 Nov 22
Active, not recruiting
Phase 3
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Start of enrollment: 2011 Apr 04
Completed
Phase 3
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Start of enrollment: 2011 Sep 01
Completed
Phase 3
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
Intergroup Trial for Children or Adolescents With B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients Start of enrollment: 2012 Jun 01
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Start of enrollment: 2013 Nov 13
Active, not recruiting
Phase 2
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 01
Join now to see all

Publications & Presentations

PubMed

Loss of humeral immunity in childhood cancer survivors not having undergone hematopoietic stem cell transplantation.
Benjamin Pearson, Michelle Pulley, Marcio Diniz, Nicole Baca, Fataneh Majlessipour> ;Cancer Reports. 2023 Dec 1
1 citations
Ganglioneuroblastoma in a Child With Neurofibromatosis Type 1: A Case Report and Literature Review.
Vivian N Okonta, Fataneh Majlessipour, Nicole M Baca> ;Journal of Pediatric Hematology/oncology. 2023 Jan 1
1 citations
Southern California Pediatric and Adolescent Cancer Survivorship (SC-PACS): Establishing a Multi-Institutional Childhood, Adolescent, and Young Adult Cancer Survivorsh...
Carol Lin, Nicole Baca, Christine Yun, Saro Armenian, David R Freyer, Fataneh Majlessipour, Lisa Mueller, Dennis J Kuo, Jacqueline Casillas, Keri Zabokrtsky, Louis Ehw...> ;Cureus. 2022 Feb 1
Transient Myeloproliferative Disorder as the Presenting Feature for Mosaic Trisomy 21.
Nicole Baca, Pedro A. Sanchez-Lara, Celeste Eno, Rhona Schreck, Fataneh Majlessipour> ;Cold Spring Harbor Molecular Case Studies. 2021 Nov 17
4 citations
Altered type 1 interferon responses in alloimmunized and nonalloimmunized patients with sickle cell disease
Emaan Madany, June Lee, Chelsea Halprin, Jina Seo, Nicole Baca, Fataneh Majlessipour, Jeanne E. Hendrickson, Samuel H. Pepkowitz, Chelsea Hayes, Ellen Klapper, David R...> ;Ejhaem. 2021 Jul 27
1 citations
RELA Fusion-Positive Ependymoma in a Child with Down Syndrome: A Case Report.
Julie L Chan, Alon Kashanian, Serguei Bannykh, Fataneh Majlessipour, Joshua J. Breunig, Moise Danielpour> ;Pediatric Neurosurgery. 2021 Mar 9
1 citations
Ewing's Sarcoma in a Patient with Crohn's Disease Treated with Ustekinumab: A Case Report
Rameshwar R. Rao, Fataneh Majlessipour, David Ziring, Nicole Baca> ;Journal of Adolescent and Young Adult Oncology. 2020 Sep 22
9 citations
The effects of everolimus on tuberous sclerosis-associated lesions can be dramatic but may be impermanent
Joseph M. Miller, Ashley Wachsman, Katherine Haker, Fataneh Majlessipour, Moise Danielpour, Dechu Puliyanda> ;Pediatric Nephrology. 2015 Jan 1
17 citations
Primary EBV infection resulting in lymphoproliferative disease in a teenager with Crohn disease.
Dominica Gidrewicz, Deborah Lehman, Shervin Rabizadeh, Fataneh Majlessipour, Marla Dubinsky> ;Journal of Pediatric Gastroenterology and Nutrition. 2011 Jan 1
366 citations
A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard...
Vassilios I. Avramis, Susan Sencer, Antonia Periclou, Harland N. Sather, Bruce Bostrom, Lewis J. Cohen, Alice G. Ettinger, Lawrence J. Ettinger, Janet Franklin, Paul S...> ;Blood. 2002 Mar 15
11 citations
Development of a double-drug-resistant human leukemia model to cytosine arabinoside and L-asparaginase: evaluation of cross-resistance to other treatment modalities.
Fataneh Majlessipour, Richard Kwock, Sagrario Martin-Aragon, Kenneth I. Weinberg, Vassilios I. Avramis> ;Anticancer Research. 2001 Jan 1
The combination regimen of idarubicin and taxotere is effective against human drug-resistant leukemic cell lines.
Majlessipour, F., Avramis, I. A., Kwock, R., Weinberg, K. I., Avrami, V. I.> ;Anticancer Res. 2002 Aug 10
Join now to see all

Hospital Affiliations

Cedars-Sinai Medical CenterLos Angeles, California